Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
$80.69M
Dr. Brian Varnum Ph.D.
69.00
Marina del Rey, CA
May 20, 1994
-1.20
$-1.86
0.21
0.25
-1,802.72%
-1.20
-0.05
-1.75
21.70
0.25
-61.90%
182.35%
Similar stocks (3)
Anixa Biosciences, Inc.
ANIX
BiomX Inc.
PHGE
Aridis Pharmaceuticals, Inc.
ARDS
ETF Exposure (6)
iShares Micro-Cap ETF
IWC
0.00594%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (3)
Anixa Biosciences, Inc.
ANIX
BiomX Inc.
PHGE
Aridis Pharmaceuticals, Inc.
ARDS
ETF Exposure (6)
iShares Micro-Cap ETF
IWC
0.00594%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%